NRSN

NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology company developing treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company focuses on combination therapies targeting multiple pathways involved in neuronal death. NeuroSense is advancing its lead candidate PrimeC through clinical trials for ALS patients.